Clinical research often lacks sufficient evidence, leading to prescribing decisions in healthcare that are not evidence-based or supported by randomized, double-blind clinical trials. This is one of the reasons why drug development takes a significant amount of time and financial resources, with an average cost of $3 billion and a duration of 12 years.

Join us for a discussion about how combining a unified clinical trial data collection platform with intelligent automation can revolutionize drug development and why the current status quo is no longer sufficient. With novel capabilities, the industry can now explore new possibilities, such as incorporating additional sensors to identify surrogate or alternative endpoints, rethinking adaptive trial designs, and quickly responding to emerging data.